cfDNA analysis from phase I/II study of lerociclib (G1T38),...

Annals of Oncology 2020 / 09 Vol. 31

cfDNA analysis from phase I/II study of lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients

Krastev, B., Rai, R., Bulat, I., Maglakelidze, M., Murias, C., Arkenau, H-T., Baird, R.D., Wardley, A.M., Roylance, R., Crijanovschi, A., Gogiladze, M., Tao, W., Beelen, A.P., Sorrentino, J.A.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.08.380
Date:
September, 2020
File:
PDF, 101 KB
2020
Conversion to is in progress
Conversion to is failed